Gatik Raises $200 Million; Series D Led by QIA and KDT as Demand for Driverless Commercial Freight Accelerates

SANTA CLARA, Calif. - Tuesday, 25. August 2026

(BUSINESS WIRE)--Gatik, the leader in autonomous trucking, today announced $200 million in financing as demand accelerates for driverless commercial freight across Fortune 50 retail, grocery and CPG supply chains. The Series D round was led by Qatar Investment Authority (QIA) and Koch Disruptive Technologies (KDT), with participation from Millennium Management, ARK Invest, Intact Private Capital and others.

Gatik has built one of the most commercially advanced businesses in autonomous freight, with more than $600 million in contracted revenue, 85,000 fully driverless orders completed, and 99% on-time delivery across its operations. Its trucks move goods across high-frequency regional networks between distribution centers and stores, giving customers a reliable way to add capacity, improve service levels and keep products moving.

“This round, led by some of the world’s leading financial institutions, is a clear validation of Gatik’s commercial leadership in autonomous freight,” said Gautam Narang, CEO and Co-founder of Gatik. “We have built Gatik with real revenue, deep customer demand, and AI-driven autonomous technology proven every day in live supply chains. This round gives us the capital to scale with speed and discipline, serve the world’s largest companies, and define the future of autonomous freight.”

“Autonomous freight is transforming the global logistics industry, making it more efficient and reliable,” said Abdulla Al-Kuwari, Head of Industrials at QIA. “QIA is committed to supporting next-generation solutions providers like Gatik that are shaping the future of freight infrastructure.”

“We've long believed autonomous freight has the potential to improve the efficiency and reliability of supply chains,” said Byron Knight, President of Koch Disruptive Technologies. “What we're seeing today is autonomy moving beyond a promising technology into real-world commercial operations. Gatik has demonstrated a practical approach to that transition, and we look forward to supporting the company's continued growth.”

The latest financing round will help Gatik expand a model built around one of the most commercially compelling applications of autonomy: high-frequency regional routes that connect distribution centers and stores. These routes are time-sensitive, operationally complex and essential to keeping shelves stocked as customer expectations shift toward faster, more predictable access to everyday products.

“Autonomous freight is reaching an inflection point as AI and robotics converge to transform the transportation ecosystem,” said Cathie Wood, Founder, CEO, and CIO of ARK Invest. “The companies creating durable value will be those that translate breakthrough innovation into scalable commercial execution. Gatik has demonstrated that autonomous trucking is moving beyond experimentation into commercially viable operations with growing customer adoption. We believe the company is well positioned to help forge the future of freight transportation.”

“We are no longer debating the potential of autonomous trucking. This category will be led by the companies that have proven technology, rigorous safety standards and the commercial discipline to operate at scale,” said Justin Smith-Lorenzetti, Managing Director, Intact Private Capital. “Gatik has built that foundation over years of operating inside complex customer supply chains. We have tripled our commitment with this latest round, driven by the conviction that Gatik has the execution record, customer traction and technical maturity to be the leader in autonomous freight across North America.”

Gatik’s AI-first AV technology is purpose-built for autonomous trucking across highways and surface streets. Its driverless trucks use dynamic routes to help customers respond to changing demand, distribution center activity and pickup and drop-off needs across commercial networks.

With dozens of driverless trucks already operating today across North America, the company plans to expand to thousands in the years ahead.

OTHER KEY INVESTOR VOICES:

“We first invested in Gatik in 2021 because we believed in the potential for autonomous freight to transform how goods move,” said Celeste Dauner, Managing Director of Koch Disruptive Technologies. “Since then, we’ve watched Gatik execute successfully against that opportunity, building scale around a focused, highly practical application of autonomy. Our decision to invest again at this stage reflects our conviction in Gatik’s model and the significant opportunity ahead for autonomous freight.”

“Autonomous trucking should meaningfully lower the cost of transporting goods and reshape modern supply chains,” said Tasha Keeney, Director of Research for Autonomous Technology and Robotics and the Director of Investment Analysis at ARK Invest. “Gatik is leading this transformation by bringing driverless technology to regional networks and unlocking value for customers. We’re excited to support Gatik as it scales autonomous freight and helps define the next era of logistics.”

About Gatik

Gatik is in the business of autonomous freight. The company operates driverless trucks daily for Fortune 50 retailers, grocers and CPG companies, moving freight between distribution centers and stores across Texas, Arizona, Arkansas, and Canada. Gatik has a strong safety record across its operations and is powered by the Gatik Driver™, a scalable, interpretable AI system purpose-built to enable safe, consistent, and high-frequency freight movement. For more information, visit gatik.ai.

Forward-Looking Statements

This news release contains “forward-looking statements” that involve substantial risks and uncertainties. Forward-looking statements generally relate to future events or Gatik’s future financial or operating performance. Forward-looking statements include information concerning possible or assumed future results of operations, including descriptions of our business plan and strategies, revenue targets and trends we expect to affect our business. These statements often include words such as “contracted,” “anticipate,” “believe,” “may,” “can,” “should,” “could,” “might,” “plan,” “possible,” “project,” “strive,” “budget,” “forecast,” “expect,” “intend,” “target”, “will,” “estimate,” “predict,” “potential,” “continue,” “scheduled”. Forward-looking statements may also be made, verbally or in writing, by members of our Board or management team in connection with this news release.

These forward-looking statements are based on management’s current expectations and beliefs. These statements are neither promises nor guarantees, but involve and are subject to known and unknown risks, uncertainties and other important factors that may cause Gatik’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by the forward-looking statements, including Gatik’s ability to execute on its growth plans, any failure to comply with laws, rules, regulations or business practices that Gatik may become subject to as a result of any expansion of its business resulting from the financing, including Gatik’s ability to successfully execute on its growth strategies and operating plans, achieve its targeted annualized contracted revenue, continue to develop its existing customer base, design and deploy an expanded fleet of trucks on behalf of customers, and diversify and expand into the market for autonomous logistics solutions. These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any forward-looking statement included in this press release speaks only as of the date of such statement. Except as required by law, Gatik disclaims any obligation to update or revise, or to publicly announce any update or revision to, any of the forward-looking statements, whether as a result of new information, future events or otherwise.

The securities described herein have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), and were offered and sold in a transaction exempt from registration under the Securities Act. The securities may not be offered or sold in the United States absent registration under the Securities Act or an applicable exemption from the registration requirements of the Securities Act.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful.

Gatik and the Gatik logo are trademarks of Gatik AI Inc. All other trademarks, service marks, and company names mentioned herein are the property of their respective owners.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260825490075/en/

Permalink
https://www.aetoswire.com/en/news/2508202656879

Contacts

Media Contact:
Aarthi Sivaraman
aarthi.sivaraman@gatik.ai

NetApp Named a Leader in the 2026 Gartner® Magic Quadrant™ for Enterprise Storage Platforms

SAN JOSE, Calif. - Wednesday, 26. August 2026

NetApp is ranked first in the Hybrid Cloud Storage Use Case in the 2026 Gartner® Critical Capabilities for Enterprise Storage Platforms

 

(BUSINESS WIRE)--NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced it has been recognized by Gartner as a Leader in the 2026 Gartner Magic Quadrant for Enterprise Storage Platforms, continuing to acknowledge NetApp as a Leader in this market from its inaugural edition of this report in 2025. The evaluation was based on specific criteria that analyzed the company’s overall Completeness of Vision and Ability to Execute. Additionally, the 2026 Gartner Critical Capabilities for Enterprise Storage Platforms report ranks NetApp first in the Hybrid Cloud Storage Use Case and second in the Hybrid Platform Services Use Case.

NetApp believes this recognition validates the company’s ability to help customers address their most pressing data challenges while offering more predictable hardware delivery timelines than its competitors. The NetApp Platform is an intelligent, governed foundation that provides zero-copy access to an organization’s data, wherever it resides. It enables seamless connections to AI and analytics ecosystems, supported by secure, best-in-class hybrid multicloud storage. By delivering real-time, in-place access to AI-ready data, it eliminates the need for constant extraction, transformation, and consolidation. With the NetApp Platform, organizations can more easily unify storage for every cloud and workload, proactively protect against evolving threats, keep their data ready for AI, and maintain the control needed to modernize with confidence and turn data into business advantage.

According to Gartner, “Enterprise storage platforms provide file, block and object data services for structured and unstructured workloads. Heads of infrastructure and IT operations can use this research to evaluate vendor platforms and support capabilities for modern storage infrastructure.”

“Even as markets, customer needs, and technology have evolved since NetApp was founded, we have been a steady and trusted leader in data infrastructure, helping organizations simplify complexity, protect their data, and turn it into business advantage,” said César Cernuda, President at NetApp. “We believe continued Gartner recognition of NetApp as a Leader, even as it has updated market definitions to reflect the changing environment, validates the consistency of our innovation and execution, as well as our ability to anticipate what customers will need next. With the NetApp Platform, we are building on that proven foundation to help customers build Intelligent Data Infrastructure, for any data, any workload, anywhere.”

In the 2026 Critical Capabilities for Enterprise Storage Platforms report, NetApp received its highest Use Case scores for Hybrid Cloud Storage and Hybrid Platform Services, which NetApp perceives as reflecting its native integrations into every major cloud combined with its unified control plane. NetApp believes these findings reinforce the value of the NetApp Platform in helping customers manage data seamlessly across hybrid multicloud environments, activate unstructured data for AI without costly movement, and operate with greater visibility, resilience, and control.

Gartner Magic Quadrant reports are a culmination of rigorous, fact-based research in specific markets, providing a wide-angle view of the relative positions of providers in markets where growth is high and provider differentiation is distinct. Providers are positioned into four quadrants: Leaders, Challengers, Visionaries and Niche Players. The research enables readers to get the most from market analysis in alignment with their unique business and technology needs.

As an essential companion to the Gartner Magic Quadrant, the Critical Capabilities report provides deeper insight into providers’ product and service offerings by extending the Magic Quadrant analysis. Enterprises can use this research to further investigate product and service ratings based on key capabilities set to important, differentiating use cases. Critical Capabilities research complements a Gartner Magic Quadrant by allowing deeper insight into the providers’ product or service offerings by identifying which ones best fit various use cases.

To read a copy of the full 2026 Gartner Magic Quadrant for Enterprise Storage Platforms report, visit: https://ntap.com/2026GartnerMQ

To read a copy of the full 2026 Gartner Critical Capabilities for Enterprise Storage Platforms report, visit: https://ntap.com/2026GartnerCC

Additional Resources

NetApp named a Leader by Gartner® in the 2025 Magic Quadrant™ for Enterprise Storage Platforms

NetApp is recognized as a 2025 Gartner® Peer Insights™ Customers’ Choice for Primary Storage Platforms

The NetApp Platform: Intelligent Data Infrastructure for the AI Era and Beyond

Register for NetApp INSIGHT 2026

Citations:

Gartner, Magic Quadrant for Enterprise Storage Platforms, Jeff Vogel, Joseph Unsworth, Julia Palmer, Chandra Mukhyala, 19 August 2026.

Gartner, Critical Capabilities for Enterprise Storage Platforms, Jeff Vogel, Joseph Unsworth, Julia Palmer, Chandra Mukhyala, 20 August 2026.

Gartner and Magic Quadrant are trademarks of Gartner, Inc. and/or its affiliates. Gartner does not endorse any company, vendor, product or service depicted in its publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner publications consist of the opinions of Gartner’s business and technology insights organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this publication, including any warranties of merchantability or fitness for a particular purpose.

About NetApp

For more than three decades, NetApp has helped the world’s leading organizations navigate change – from the rise of enterprise storage to the intelligent era defined by data and AI. Today, NetApp is the Intelligent Data Infrastructure company, helping customers turn data into a catalyst for innovation, resilience, and growth.

At the heart of that infrastructure is the NetApp data platform – the unified, enterprise-grade, intelligent foundation that connects, protects, and activates data across every cloud, workload, and environment. Built on the proven power of NetApp ONTAP, our leading data management software and OS, and enhanced by automation through the AI Data Engine and AFX, it delivers observability, resilience, and intelligence at scale.

Disaggregated by design, the NetApp data platform separates storage, services, and control so enterprises can modernize faster, scale efficiently, and innovate without lock-in. As the only enterprise storage platform natively embedded in the world’s largest clouds, it gives organizations the freedom to run any workload anywhere with consistent performance, governance, and protection.

With NetApp, data is always ready – ready to defend against threats, ready to power AI, and ready to drive the next breakthrough. That’s why the world’s most forward-thinking enterprises trust NetApp to turn intelligence into advantage.

Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.

NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260826435523/en/

Permalink

https://www.aetoswire.com/en/news/2608202656899

Contacts

Media Contact:

Kenya Hayes

NetApp

kenya.hayes@netapp.com

Investor Contact:

Kris Newton

NetApp

kris.newton@netapp.com

BeOne Medicines Announces U.S. FDA Approval for TEVIMBRA-Based Regimen for First-Line HER2+ GEA

 

SAN CARLOS, Calif. 

TEVIMBRA plus ZIIHERA and chemotherapy is the first and only immunotherapy-based regimen to deliver more than two years of median OS in first-line HER2+ GEA, regardless of PD-L1 status

Regimen poised to become standard of care in this difficult-to-treat disease.

(BUSINESS WIRE) -- BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of adult patients with unresectable locally advanced or metastatic HER2-positive (HER2+) gastric, gastroesophageal junction, or esophageal adenocarcinoma (GEA). The approval is supported by results from the Phase 3 HERIZON-GEA-01 trial, which were published in The New England Journal of Medicine earlier this year.

GEA, which includes adenocarcinomas of the stomach, gastroesophageal junction and esophagus, remains an area of substantial unmet need in the United States, with more than 31,000 new stomach cancer cases diagnosed each year.1 Approximately 20% of patients with GEA have HER2+ disease, a subtype that has historically been difficult to treat.2,3,4

Despite recent advances, long-term outcomes for patients with advanced or metastatic HER2+ GEA remain challenging and the need for more effective first-line options is urgent. In the U.S., fewer than 40% of patients survive beyond two years. These outcomes highlight the need for additional treatment options that may help extend survival for patients facing this disease.

Jaffer A. Ajani, M.D., Professor of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, said:

“For patients with advanced HER2-positive gastroesophageal adenocarcinoma, first-line treatment represents a critical opportunity to make the greatest possible impact and change the course of disease at the start of care, making it especially important to provide the most effective treatment options and combinations upfront to give patients the best possible chance for improved outcomes. The median overall survival of more than two years observed with this regimen demonstrates meaningful progress in a setting where outcomes have historically been challenging to improve. With benefit observed across PD-L1 subgroups, this approval gives physicians greater freedom to select treatment regardless of PD-L1 status.”

Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne Medicines, said:

“Today’s approval is an important milestone for BeOne as we continue to expand the impact of TEVIMBRA for patients living with cancer. As the first approved foundational asset to emerge from our solid tumor portfolio, TEVIMBRA has demonstrated the potential to address significant unmet needs across tumor types, and today’s approval further reinforces our commitment to advancing innovative, practice changing combination regimens with TEVIMBRA for patients facing difficult-to-treat cancers. We are proud to bring this new first-line treatment option to physicians and patients with HER2-positive gastroesophageal adenocarcinoma in the United States.”

Aki Smith, Founder & Executive Director, Hope for Stomach Cancer, said:

“For people living with HER2-positive gastroesophageal cancer and their families, the possibility of more time can mean everything - more moments with loved ones, more milestones, and more confidence that progress is being made in a disease where additional options are urgently needed. As a caregiver to my father, who faced HER2-positive gastroesophageal cancer, I know personally the fear and urgency families feel when treatment begins and how much it means to have more options available from the very start. We welcome the availability of this new regimen and remain committed to helping patients and caregivers understand their treatment options and access the support they need throughout their journey.”

Approval supported by Phase 3 HERIZON-GEA-01 results

The approval is based on data from HERIZON-GEA-01, the global Phase 3 clinical trial evaluating ZIIHERA plus chemotherapy, with and without TEVIMBRA, compared with trastuzumab plus chemotherapy as first-line treatment for advanced or metastatic HER2+ GEA.

Key findings from the trial include:

Overall survival (OS): TEVIMBRA plus ZIIHERA and chemotherapy demonstrated a statistically significant improvement in OS, with median OS of 26.4 months compared with 19.2 months in the control arm.

Progression-free survival (PFS): TEVIMBRA plus ZIIHERA and chemotherapy demonstrated a statistically significant and clinically meaningful improvement in PFS, with a median PFS of 12.4 months compared with 8.1 months in the control arm.

Consistent benefit regardless of PD-L1 status: improvements in OS and PFS were observed across patient subgroups, including patients with PD-L1-negative tumors (TAP <1%), where median OS was 29.7 months with TEVIMBRA plus ZIIHERA and chemotherapy compared with 15.8 months in the control arm.

Consistent efficacy across HER2 expression levels: TEVIMBRA + ZIIHERA and chemotherapy showed benefit in both HER2 IHC (immunohistochemistry) 3+ and HER2 IHC 2+ populations.

Safety: treatment with TEVIMBRA plus ZIIHERA and chemotherapy was generally consistent with the known safety profiles of the components of the regimen, and no new safety signals were identified.

About the HERIZON-GEA-01 Phase 3 Trial

HERIZON-GEA-01 (NCT05152147) is a global, randomized, open-label Phase 3 trial, conducted jointly with Jazz Pharmaceuticals, to evaluate and compare the efficacy and safety of ZIIHERA plus chemotherapy, with and without TEVIMBRA, to the standard of care (trastuzumab plus chemotherapy) as first-line treatment for adult patients with advanced/metastatic HER2+ GEA. The trial randomized 914 patients from approximately 300 trial sites in more than 30 countries. Patients for this trial had unresectable locally advanced, recurrent or metastatic HER2+ GEA (adenocarcinomas of the stomach or esophagus, including the gastroesophageal junction), defined as 3+ HER2 expression by IHC or 2+ HER2 expression by IHC with ISH positivity per central assessment. Patients were randomized to the three trial arms: ZIIHERA in combination with chemotherapy and TEVIMBRA; ZIIHERA in combination with chemotherapy; and trastuzumab plus chemotherapy. The trial is evaluating dual primary endpoints, PFS per blinded independent central review (BICR) and OS.

About ZIIHERA (zanidatamab-hrii)

ZIIHERA (zanidatamab) is a bispecific human epidermal growth factor receptor 2, or HER2-directed antibody that binds to two extracellular sites on HER2. Binding of zanidatamab with HER2 results in internalization leading to a reduction in HER2 expression of the receptor on the tumor cell surface. Zanidatamab induces complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP). These mechanisms result in tumor growth inhibition and cell death in vitro and in vivo.5

Zanidatamab is being developed in multiple clinical trials as a targeted treatment option for patients with solid tumors that express HER2. Zanidatamab is approved in China for the treatment of patients who have unresectable, locally advanced, or metastatic HER2-high expression (IHC 3+) biliary tract cancer (BTC) and who have received prior systemic therapy. ZIIHERA has also been granted accelerated approval in the U.S. and conditional marketing authorization in the European Union for eligible BTC patients. Zanidatamab is being developed by Jazz and BeOne under license agreements from Zymeworks, which first developed the molecule. BeOne has licensed zanidatamab from Zymeworks in Asia (excluding India and Japan), Australia and New Zealand. Jazz Pharmaceuticals has rights in all other regions.

ZIIHERA is a registered trademark of Zymeworks BC Inc.

About TEVIMBRA (tislelizumab-jsgr)

TEVIMBRA is a uniquely designed humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody with high affinity and binding specificity against PD-1. It is designed to minimize binding to Fc-gamma (Fcγ) receptors on macrophages, helping to aid the body’s immune cells to detect and fight tumors.

TEVIMBRA is the foundational asset of BeOne’s solid tumor portfolio and has shown potential across multiple tumor types and disease settings. The global TEVIMBRA clinical development program includes almost 15,000 patients enrolled to date in 30+ countries and regions across 71 trials, including 21 registration-enabling studies. TEVIMBRA is approved in over 50 countries, and more than 2 million patients have been treated globally.

Select Important Safety Information

Serious and sometimes fatal adverse reactions occurred with TEVIMBRA treatment. Warnings and Precautions include severe and fatal immune-mediated adverse reactions, including pneumonitis, colitis, hepatitis, endocrinopathies, nephritis with renal dysfunction, dermatologic adverse reactions, and solid organ transplant rejection. Other warnings and precautions include infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.

The most common adverse reactions (≥20%), including lab abnormalities, in patients receiving TEVIMBRA + zanidatamab + chemotherapy were diarrhea, nausea, anemia, decreased appetite, vomiting, decreased neutrophil count, hypokalemia, fatigue, rash, decreased platelet count, peripheral neuropathy, infusion-related reaction, and increased aspartate aminotransferase.

Please see full U.S. Prescribing Information including the U.S. Medication Guide.

The information in this press release is intended for a global audience. Product indications vary by region.

About BeOne

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before. To learn more about BeOne, please visit www.beonemedicines.com and follow us on LinkedIn, X, Facebook and Instagram.

Forward-Looking Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including the potential of TEVIMBRA to address significant unmet needs across tumor types; BeOne’s commitment to advancing combination regimens with TEVIMBRA; the potential of TEVIMBRA plus ZIIHERA and chemotherapy to become a new standard of care for treating HER2+ GEA; statements regarding the potential benefits of TEVIMBRA and ZIIHERA; and BeOne’s plans, commitments, aspirations, and goals under the heading “About BeOne.” Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials and marketing approval; BeOne's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne's ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne’s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products and its ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled “Risk Factors” in BeOne’s most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeOne's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.

To access BeOne media resources, please visit our Newsroom site.

1 American Cancer Society. Key Statistics About Stomach Cancer. American Cancer Society. Updated: February 27, 2026. https://www.cancer.org/cancer/types/stomach-cancer/key-statistics.html

2 Abrahao-Machado I.F., et al. HER2 testing in gastric cancer: An update. World J Gastroenterol. 2016;22(19):4619–4625.

3 Van Cutsem E., et al. HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer. 2015;18(3):476–484

4 Stroes, C.I., et al. A systematic review of HER2 blockade for the curative treatment of gastroesophageal adenocarcinoma: Successes achieved and opportunities ahead. Cancer Treat Rev. 2021;99:102249.

5 ZIIHERA (zanidatamab-hrii) Prescribing Information. Palo Alto, CA: Jazz Pharmaceuticals, Inc.).

 

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260825943679/en/

Permalink

https://www.aetoswire.com/en/news/2508202656883

Contacts

Investor Contact

Liza Heapes

+1 857-302-5663

ir@beonemed.com

Media Contact

Kyle Blankenship

+1 667-351-5176

media@beonemed.com

The LYCRA Company Reimagines the Trade Show Experience at Intertextile

 WILMINGTON, Del. - Wednesday, 26. August 2026

Immersive Co-Creation District Showcases New Fiber Innovations and Value Chain Collaboration

 

(BUSINESS WIRE)--The LYCRA Company, a global leader in fiber and technology solutions for the apparel industry, is reimagining the trade show experience at Intertextile Shanghai Apparel Fabrics Autumn Edition, which opened today in China. Building on the success of last year's ALL IN concept, the company has expanded its co-creation vision into a 356-square-meter Lifestyle District featuring partners Jingzili New Material, JYT Textile, Lianxingfa Knitting, and Trend Textile. The district is part of a larger 895-square-meter pavilion showcasing a total of 19 co-exhibitors. Together, they demonstrate how innovations in fiber, fabric, and garments can be combined to create compelling solutions for both work and play.

“The apparel industry is built on creativity, and great ideas emerge when people with different perspectives come together,” said Jason Wang, vice president, Asia, The LYCRA Company. “This year, we wanted to create an environment that sparks curiosity, encourages new thinking, and showcases what's possible when innovation moves beyond individual products to become part of a broader experience. Intertextile provides an ideal setting to share that vision and inspire what's next for our industry.”

Across the pavilion, LYCRA®, COOLMAX®, and THERMOLITE® brand innovations are showcased through commercial apparel applications that demonstrate how performance, comfort, and sustainability can help address evolving consumer and industry needs.

New for wovens, COOLMAX CloakFX™ fiber helps mask the appearance of sweat on fabric, delivers wet and dry fabric opacity, or anti-see-through performance, while also providing moisture management. Made with 100% recycled PET and certified under the Global Recycled Standard, it helps reduce reliance on virgin raw materials.

LYCRA FiT400™ fiber for both wovens and knits is being previewed at Intertextile. The knits version has been refreshed and is now available in three performance tiers: Essential, Expanded, and Elevated, allowing brands to select the level of functionality and sustainability that best suits their needs. It also delivers non-spandex stretch and cooling benefits that last the life of the garment. The woven version creates fabrics that offer traditional aesthetics with durable, low-to-moderate mechanical stretch for all-day comfort.

RENEWABLE LYCRA® fiber is made with 70% renewable content derived in part from field corn grown in the American Midwest. It delivers the same performance as traditional LYCRA® fiber while also supporting efforts to reduce garment carbon footprints.

Ebru Ozaydin, product category director, denim & ready-to-wear, The LYCRA Company, will present “Designed for Real Life: How Performance Wovens Are Reshaping the Everyday Wardrobe” on Wednesday, Aug. 26, at 10 a.m. China Standard Time at Stage H4.1-A149. The session will explore COOLMAX CloakFX™ fiber and other innovations designed for workwear, performance fabrics, and everyday apparel applications.

Visitors can explore The LYCRA Company's Lifestyle District and pavilion at Hall 4.1-E56 throughout the Intertextile exhibition. Applications on display span performance apparel, workwear, denim, and everyday essentials, illustrating how ingredient-brand technologies are being translated into commercially relevant products that meet consumer needs.

About The LYCRA Company

The LYCRA Company is a leading global fiber and technology solutions provider to the apparel and personal care industries, committed to offering sustainable products made with renewable, pre- and post-consumer recycled ingredients that reduce waste and help set the stage for circularity. Headquartered in Wilmington, Delaware, United States, it owns the LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX®, and TACTEL® brands. The LYCRA Company adds value to its customers’ products by offering unique innovations that meet the consumer’s need for comfort and lasting performance. Learn more at thelycracompany.com.

LYCRA®, COOLMAX® and THERMOLITE® are trademarks of The LYCRA Company.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260821281698/en/

Permalink

https://www.aetoswire.com/en/news/2608202656884

Contacts

Eva Chen

Eva.Chen@lycra.com

 

Moody’s Brings Its Decision-Grade Intelligence to Gemini Enterprise for Financial Services

 NEW YORK - Tuesday, 25. August 2026

Integration through Moody’s Credit MCP server brings trusted credit ratings, research, and entity intelligence into Google Cloud’s new industry-specific AI solution for financial services

 

(BUSINESS WIRE)--Moody’s Corporation (NYSE: MCO) today announced that its connected intelligence is now available in Google Cloud’s Gemini Enterprise for Financial Services through the Moody’s Credit Model Context Protocol (MCP) server. As a launch partner for Google Cloud’s Gemini Enterprise for Financial Services, Moody’s gives financial professionals working in the platform direct access to credit ratings and research from Moody’s Ratings, along with Moody’s curated intelligence on companies, entities, and risk.

“Delivering decision-grade intelligence wherever financial professionals work is how we help our customers stay ahead as agentic AI reshapes financial workflows,” said Ana Meauta, Managing Director, Channel Sales Partnerships at Moody’s. “With Gemini Enterprise for Financial Services, our customers can access Moody’s connected intelligence directly, bringing contextualized, decision-grade data to the point of decision.”

Gemini Enterprise for Financial Services is Google Cloud’s industry-specific AI solution, pairing purpose-built skills and agents with the specialized data sources financial professionals use for complex work. Moody’s Credit MCP server powers the platform to draw directly on Moody’s content at the protocol level, grounding AI outputs in trusted, explainable data while eliminating the need for custom integrations.

With Moody’s intelligence available natively in the platform, financial professionals can ground AI-driven research and analysis across a range of credit and risk workflows, from credit analysis and counterparty assessment to entity screening and market research, helping teams move faster across the tasks they navigate each day without leaving the environment where they work.

“By bringing Moody’s trusted financial intelligence directly into Gemini Enterprise for Financial Services, we are enabling financial professionals to streamline complex workflow without friction. This integration ensures that teams can access authoritative, auditable data right where they work, significantly accelerating analysis while maintaining the highest standard of accuracy and trust,” said Satish Thomas, Vice President, Google Cloud.

The integration expands Moody’s partnership with Google Cloud and reflects Moody’s broader AI strategy of delivering its connected intelligence to customers inside the platforms and workflows they already use. Each integration is a new access point into one connected system, delivering the same trusted intelligence Moody’s customers use to make informed decisions about risk.

To learn more, visit https://www.moodys.com/web/en/us/creditview/blog/ai-partnerships.html.

About Moody’s Corporation

In a world shaped by increasingly interconnected risks, Moody’s (NYSE: MCO) data, insights, and innovative technologies help customers develop a holistic view of their world and unlock opportunities. With a rich history of experience in global markets and a diverse workforce of approximately 16,000 across more than 40 countries, Moody’s gives customers the comprehensive perspective needed to act with confidence and thrive. Learn more at moodys.com.

“Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995

Certain statements contained in this document are forward-looking statements and are based on future expectations, plans and prospects for Moody’s business and operations that involve a number of risks and uncertainties. Such statements involve estimates, projections, goals, forecasts, assumptions and uncertainties that could cause actual results or outcomes to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements. Stockholders and investors are cautioned not to place undue reliance on these forward-looking statements. The forward-looking statements and other information in this document are made as of the date hereof, and Moody’s undertakes no obligation (nor does it intend) to publicly supplement, update or revise such statements on a going-forward basis, whether as a result of subsequent developments, changed expectations or otherwise, except as required by applicable law or regulation. Factors, risks and uncertainties as well as other risks and uncertainties that could cause Moody’s actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements are described in greater detail under “Risk Factors” in Part I, Item 1A of Moody’s annual report on Form 10-K for the year ended December 31, 2025, and in other filings made by the Company from time to time with the SEC or in materials incorporated herein or therein. Stockholders and investors are cautioned that the occurrence of any of these factors, risks and uncertainties may cause the Company’s actual results to differ materially from those contemplated, expressed, projected, anticipated or implied in the forward-looking statements, which could have a material and adverse effect on the Company’s business, results of operations and financial condition.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260825935084/en/

Permalink

https://www.aetoswire.com/en/news/2508202656877

Contacts

For Moody’s Communications:

Joe Mielenhausen

Moody’s Corporation

+1 212-553-1461

joe.mielenhausen@moodys.com

 

IFF Report Finds GLP-1 Is Reshaping Food Choices and Eating Behaviors Among Indian Consumers

 Research highlights emerging opportunities for food and beverage innovation

 

(BUSINESS WIRE)--IFF (NYSE: IFF) — a global leader in flavors, fragrances and health and biosciences — released new research examining how GLP-1 use is influencing food behaviors among Indian consumers and what those shifts may mean for the future of food and beverage innovation. The study is the latest in IFF’s GLP-1 global consumer insights following the company’s 2025 GLP-1 Consumer Opportunity Outlook.

“We are seeing that a change in appetite can lead to a broader change in the relationship people have with food, from how much consumers eat to how they choose, experience and participate in eating occasions,” said Harsch Koshti, regional marketing director, IFF Taste for Greater Asia. “For the food industry, this is a critical opportunity to listen closely to these emerging behaviors and think about how innovation can address these needs.”

The report, "Inside the India GLP-1 Consumer Journey," was unveiled at IFF’s Eat Smart Asia: The GLP-1 Shift symposium in New Delhi. Based on research conducted among GLP-1 users in Delhi, Mumbai and Bengaluru, the study explores how changing appetites are influencing food choices, sensory experiences, shopping habits and social eating occasions. The findings suggest a new consumer mindset is emerging. While participants reported eating smaller portions, they are also becoming more deliberate about what they consume, placing greater emphasis on nutrition, taste, ingredient quality and overall eating satisfaction. Key findings from the report include:

74% say they read food labels more carefully than before starting GLP-1 medication

64% experience social eating discomfort at least occasionally

69% are choosing coconut water as part of their hydration habits

The Indian plate is getting smaller, but the desire for food Isn't disappearing

The consumer study points to significant changes in portion sizes across everyday Indian foods. For example, consumers are moving from three to four chapatis to one or two, from five or six idlis to two, and from 2.5 bowls of rice to half a bowl of serving. Reduction in quantity for consumption does not diminish the importance of food. Instead, when consumers eat less, every bite has to work harder — increasing the importance of nutrient density, taste, texture and satisfaction.

Research from IFF’s India GLP-1 consumer journey report also found notable changes in sensory perception, suggesting opportunities for food developers to create products that deliver enhanced nutrition and sensory satisfaction in smaller portions. For example:

90% experience changes in how food tastes or feels

50% prefer soft, easy-to-digest texture

69% want to balance flavor impact

Beyond individual eating habits, the research highlights the social dimensions of changing consumption patterns. Nearly two-thirds of respondents indicated they experience some level of discomfort during social eating occasions. The report’s findings suggest many consumers remain motivated by participation and normalcy, creating opportunities for brands to develop products and experiences that help consumers remain engaged in familiar food occasions while adapting to changing needs.

The GLP-1 consumer is becoming a more deliberate food shopper

The report points to a significant shift in how consumers approach food information — 74% say they read food labels more carefully than before. The scrutiny extends beyond calories to protein, ingredients and natural or preservative-free claims. For food and beverage brands, this raises a broader question about how products communicate nutrition, ingredients and value to consumers who are increasingly deliberate about what makes it onto their plates.

The individual plate is changing faster than the family grocery basket

While personal consumption habits are evolving, household purchasing patterns remain relatively stable. Among respondents:

78% continue buying biscuits for their households

71% continue buying packaged sweets and full-fat dairy products

63% continue buying fried snacks

This creates a more complex opportunity for food and beverage brands than simply developing “GLP-1-friendly” products, particularly in a market where food choices remain deeply embedded in household and family routines.

Hydration is becoming more intentional

The shift extends beyond solid food. The study found that 74% view hydration as a daily wellness goal, with many gravitating toward coconut water and electrolyte-based beverages.

The trend highlights growing interest in products that combine functionality, hydration and sensory appeal as consumers become more intentional about their beverage choices.

Implications for food and beverage innovation

The research further highlights that the opportunity surrounding GLP-1 extends beyond weight management. As consumer expectations around appetite, portions and sensory experiences continue to evolve, food and beverage companies may need to reconsider how they deliver nutrition, enjoyment and value across eating occasions.

IFF’s report, “Inside the India GLP-1 Consumer Journey,” provides an early perspective on changing consumer behaviors and emerging opportunities across food, beverage and sensory innovation.

Access the full report here.

The findings are based on a consumer insights study conducted among GLP-1 users in Delhi, Mumbai and Bengaluru and are intended for informational purposes only. They do not constitute medical, nutritional or healthcare advice.

Welcome to IFF

At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in taste, scent and health and biosciences, we’re innovating for the future. Every day, we deliver groundbreaking, sustainable solutions that elevate products people love — advancing wellness, delighting the senses and enhancing the human experience. Learn more at iff.com, LinkedIn, Instagram and Facebook.

© 2026 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260824816059/en/

Permalink

https://aetoswire.com/en/news/2508202656864

Contacts

Taste Communications:

Lynette Wong

+65 8093 0122

Lynette.wong@iff.com

SLB Selected as Strategic Reservoir Partner for the Havstjerne Carbon Storage Project

 Integrated engineering work will support development of the large-scale carbon storage project ahead of a final investment decision

(BUSINESS WIRE) -- Global energy technology company SLB (NYSE: SLB) today announced it has been selected as strategic reservoir partner for the Havstjerne carbon storage project in the Norwegian North Sea, providing technology and engineering services for the concept and front-end engineering and design (FEED) phases. The Havstjerne project is a large-scale offshore carbon storage development in Norway intended to serve industrial emitters across Europe, operated by Harbour Energy (LSE: HBR) in consortium with Stella Maris CCS, a Yinson Production company.

SLB will coordinate an integrated project scope that connects analysis of the underground storage reservoir with injection well design, subsea infrastructure and plans for monitoring stored CO2 as the Havstjerne partnership develops the project’s technical, cost and schedule basis ahead of a final investment decision. The scope includes concept and FEED studies delivered through close collaboration between SLB and its OneSubsea™ joint venture.

"Carbon storage projects are moving from individual technical studies toward integrated development models that connect the subsurface, wells and offshore infrastructure,” said Gavin Rennick, president of SLB’s New Energy and Industrial business. "Havstjerne demonstrates how SLB can bring together its technology, engineering and project integration capabilities to help customers develop the technical basis needed to advance large-scale carbon storage projects.”

SLB will provide the early engineering study, subsurface and reservoir maturation and wells, while SLB OneSubsea will deliver the concept and FEED of the subsea injection system, comprising the template manifold, all-electric trees, control system, umbilical and distribution system. This integrated approach is intended to improve technical coordination across the storage system and reduce the number of technical and contractual interfaces.

An appraisal well drilled in 2025 confirmed reservoir quality suitable for CO2 injection and storage, providing an important technical basis for the project’s continued development. The Havstjerne project also received 225 million euros from the EU Innovation Fund in 2025 and has selected a low-pressure floating storage and injection concept focused on system reliability, low cost and commercial flexibility.

"Havstjerne is being matured to provide a cost-effective, large-scale offshore CO2 storage for European industrial emitters,” said Mark van Aerssen, Havstjerne project manager. "This integrated approach will help us further define the project’s technical, cost and schedule basis while strengthening coordination across critical interfaces.”

"The Havstjerne project demonstrates how collaboration across the value chain can help advance carbon storage solutions,” said Lars Gunnar Vogt, chief technical officer of Yinson Production. "We believe large-scale, cost-competitive CO2 storage infrastructure will play an important role in serving industrial emitters, and we look forward to continuing our collaboration with Harbour Energy and SLB.”

Key points:

SLB was selected as strategic reservoir partner for the concept and front-end engineering and design (FEED) phases of the Havstjerne carbon storage project in the Norwegian North Sea.

Havstjerne is intended to provide large-scale offshore CO2 storage for European industrial emitters and received 225 million euros from the EU Innovation Fund in 2025.

SLB will coordinate an integrated scope that includes concept and FEED studies, subsurface and reservoir maturation, wells and the subsea injection system, delivered through close collaboration between SLB and its OneSubsea™ joint venture.

The integrated work will help the Havstjerne partnership develop the project’s technical, cost and schedule basis ahead of a final investment decision. Havstjerne has selected a low-pressure floating storage and injection concept focused on system reliability, low cost and commercial flexibility.

About SLB

SLB (NYSE: SLB) is a global technology company that has driven energy innovation for 100 years. With a global footprint in more than 100 countries and employees representing almost twice as many nationalities, we work each day on innovating oil and gas, delivering digital at scale, decarbonizing industries, and developing and scaling new energy systems that accelerate the energy transition. Find out more at slb.com.

Cautionary Statement Regarding Forward-Looking Statements:

This press release contains “forward-looking statements” within the meaning of the U.S. federal securities laws — that is, statements about the future, not about past events. Such statements often contain words such as “expect,” “may,” “can,” “estimate,” “intend,” “anticipate,” “will,” “potential,” “projected" and other similar words. Forward-looking statements address matters that are, to varying degrees, uncertain, such as forecasts or expectations regarding the deployment of, or anticipated benefits of, SLB’s new technologies and partnerships; and improvements in operating procedures and technology. These statements are subject to risks and uncertainties, including, but not limited to, the inability to recognize intended benefits of SLB’s strategies, initiatives or partnerships; and other risks and uncertainties detailed in SLB’s most recent Forms 10-K, 10-Q and 8-K filed with or furnished to the U.S. Securities and Exchange Commission. If one or more of these or other risks or uncertainties materialize (or the consequences of such a development changes), or should underlying assumptions prove incorrect, actual outcomes may vary materially from those reflected in our forward-looking statements. The forward-looking statements speak only as of the date of this press release, and SLB disclaims any intention or obligation to update publicly or revise such statements, whether as a result of new information, future events or otherwise.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260825382216/en/

Permalink

https://aetoswire.com/en/news/2508202656878

Contacts

Media

Josh Byerly – SVP of Global Communications

Moira Duff – Director of External Communications

SLB

Tel: +1 (713) 375-3407

media@slb.com

Investors

James R. McDonald – SVP of Investor Relations & Industry Affairs

Joy V. Domingo – Director of Investor Relations

SLB

Tel: +1 (713) 375-3535

investor-relations@slb.com